INFO & CONTACTS:  +39 02 2390 1

AIRC IG 2018 (ID 21939): Personalized Therapy of Metastatic Thyroid Cancer — Biological Characterization and Optimization With ¹²⁴I PET Dosimetry: A Two-Center, Single-Arm, Phase II Prospective Study

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Maccauro Marco

Main Facility: Medicina Nucleare

Drug:  Iodine-124 (for PET imaging and dosimetry)

 Iodine-131 (for targeted)

Pathologies: Other

ClinicalTrials.gov: Read more about clinical trials

This is a two-center, prospective,single-arm Phase II study aimed at optimizing personalized treatment strategies for patients with metastatic thyroid cancer through advanced imaging and dosimetry. 

The study evaluates the use of an experimental diagnostic radiopharmaceutical, Iodine-124 (¹²⁴I), combined with positron emission tomography (PET) imaging to perform patient-specific dosimetry. This approach enables precise quantification of iodine uptake in metastatic lesions, allowing clinicians to tailor subsequent therapeutic dosing with radioiodine (¹³¹I). 

Key objectives include improving treatment efficacy, minimizing toxicity, and enhancing patient selection for radioiodine therapy by integrating biological characterization with quantitative imaging. 

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe